B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy
Our recent study showed high rate of HBsAg seroconversion achieved in inactive HBsAg carriers (IHCs) treated with peginterferon (PEG-IFN). To better understand the immune-mediated component to the HBsAg seroconversion, we investigated the role of B cells in this study. A total of 44 IHCs were given...
Gespeichert in:
| Veröffentlicht in: | PloS one 2020-12, Vol.15 (12), p.e0242559-e0242559 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0242559 |
|---|---|
| container_issue | 12 |
| container_start_page | e0242559 |
| container_title | PloS one |
| container_volume | 15 |
| creator | Cao, Zhenhuan Meng, Sha Zheng, Yanhong Wang, Junli Wang, Rui Chen, Xinyue |
| description | Our recent study showed high rate of HBsAg seroconversion achieved in inactive HBsAg carriers (IHCs) treated with peginterferon (PEG-IFN). To better understand the immune-mediated component to the HBsAg seroconversion, we investigated the role of B cells in this study. A total of 44 IHCs were given 48 weeks of PEG-IFN. Fifteen cases achieve HBsAg seroconversion (R group), whereas 29 failed (NR group). The proportion of total B cells and plasma B cells were measured before and during treatment. We found that the proportion of total B cells and plasma B cells was no significant between R group and NR group at baseline, but significantly higher in R group than NR group during PEG-IFN treatment, even when the exact age-, sex-, and treatment period-match was made. In conclusion, we demonstrated the increase of total B cell and plasma B cells during PEG-IFN treatment favored HBsAg seroconversion for IHC, and B cells may play a role in HBV seroconversion. |
| doi_str_mv | 10.1371/journal.pone.0242559 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2466255374</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A643546224</galeid><doaj_id>oai_doaj_org_article_273ee106327b42d88e320e5cf32fb545</doaj_id><sourcerecordid>A643546224</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-90d10d51c956db95296769d5208f00bc90a7c51adf5c3eb49a9580d617a23da23</originalsourceid><addsrcrecordid>eNqNk11v0zAUhiMEYmPwDxBEQkJw0eLYsV3fIHUTsEqTJvF1aznOSerKjYvtdOzf49BsatAukGMlsp_3PfE5Pln2skDzgvDiw8b1vlN2vnMdzBEuMaXiUXZaCIJnDCPy-Oj7JHsWwgYhShaMPc1OCMGsJASdZu15rsHakN-Ah9yDVRHqPLr88jws2zyAd9p1e_DBuC43w6N0NHsYAa28N2k3b5y17sZ0bb6D1nQRfJO0XR7X4NXu9nn2pFE2wIvxfZb9-Pzp-8Xl7Or6y-pieTXTTOA4E6guUE0LLSirK0GxYJyJmmK0aBCqtECKa1qouqGaQFUKJegC1azgCpM6zbPs9cF3Z12QY46CxCVjKUGEl4lYHYjaqY3cebNV_lY6ZeTfBedbqXw02oLEnAAUiBHMqxLXiwUQjIDqhuCmoiVNXh_HaH21hVpDF72yE9PpTmfWsnV7yXmBkGDJ4N1o4N2vHkKUWxOGgqgOXH_4b84JFyShb_5BHz7dSLUqHcB0jUtx9WAql6nktGQYD9T8ASqNGrYm1Rsak9YngvcTQWIi_I6t6kOQq29f_5-9_jll3x6xa1A2roOzfUy3LUzB8gBq70Lw0NwnuUBy6Ie7bMihH-TYD0n26rhA96K7BiB_AGJzBL8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2466255374</pqid></control><display><type>article</type><title>B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Cao, Zhenhuan ; Meng, Sha ; Zheng, Yanhong ; Wang, Junli ; Wang, Rui ; Chen, Xinyue</creator><contributor>Chemin, Isabelle</contributor><creatorcontrib>Cao, Zhenhuan ; Meng, Sha ; Zheng, Yanhong ; Wang, Junli ; Wang, Rui ; Chen, Xinyue ; Chemin, Isabelle</creatorcontrib><description>Our recent study showed high rate of HBsAg seroconversion achieved in inactive HBsAg carriers (IHCs) treated with peginterferon (PEG-IFN). To better understand the immune-mediated component to the HBsAg seroconversion, we investigated the role of B cells in this study. A total of 44 IHCs were given 48 weeks of PEG-IFN. Fifteen cases achieve HBsAg seroconversion (R group), whereas 29 failed (NR group). The proportion of total B cells and plasma B cells were measured before and during treatment. We found that the proportion of total B cells and plasma B cells was no significant between R group and NR group at baseline, but significantly higher in R group than NR group during PEG-IFN treatment, even when the exact age-, sex-, and treatment period-match was made. In conclusion, we demonstrated the increase of total B cell and plasma B cells during PEG-IFN treatment favored HBsAg seroconversion for IHC, and B cells may play a role in HBV seroconversion.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0242559</identifier><identifier>PMID: 33264330</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Acquired immune deficiency syndrome ; Adult ; Age ; AIDS ; Antigens ; B cells ; B-Lymphocytes - immunology ; Biology and Life Sciences ; Carrier State - immunology ; Carriers ; Case-Control Studies ; Deoxyribonucleic acid ; DNA ; Dosage and administration ; Female ; Flow cytometry ; Hepatitis B surface antigen ; Hepatitis B Surface Antigens - blood ; Hospitals ; Humans ; Interferon ; Interferons - therapeutic use ; Liver diseases ; Lymphocytes B ; Male ; Medicine and Health Sciences ; Monoclonal antibodies ; Peginterferon alfa-2a ; Physiological aspects ; Plasma ; Plasma Cells - immunology ; Polyethylene Glycols - therapeutic use ; Research and Analysis Methods ; Seroconversion</subject><ispartof>PloS one, 2020-12, Vol.15 (12), p.e0242559-e0242559</ispartof><rights>COPYRIGHT 2020 Public Library of Science</rights><rights>2020 Cao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Cao et al 2020 Cao et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-90d10d51c956db95296769d5208f00bc90a7c51adf5c3eb49a9580d617a23da23</citedby><cites>FETCH-LOGICAL-c692t-90d10d51c956db95296769d5208f00bc90a7c51adf5c3eb49a9580d617a23da23</cites><orcidid>0000-0003-4204-1049</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710096/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710096/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79343,79344</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33264330$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Chemin, Isabelle</contributor><creatorcontrib>Cao, Zhenhuan</creatorcontrib><creatorcontrib>Meng, Sha</creatorcontrib><creatorcontrib>Zheng, Yanhong</creatorcontrib><creatorcontrib>Wang, Junli</creatorcontrib><creatorcontrib>Wang, Rui</creatorcontrib><creatorcontrib>Chen, Xinyue</creatorcontrib><title>B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Our recent study showed high rate of HBsAg seroconversion achieved in inactive HBsAg carriers (IHCs) treated with peginterferon (PEG-IFN). To better understand the immune-mediated component to the HBsAg seroconversion, we investigated the role of B cells in this study. A total of 44 IHCs were given 48 weeks of PEG-IFN. Fifteen cases achieve HBsAg seroconversion (R group), whereas 29 failed (NR group). The proportion of total B cells and plasma B cells were measured before and during treatment. We found that the proportion of total B cells and plasma B cells was no significant between R group and NR group at baseline, but significantly higher in R group than NR group during PEG-IFN treatment, even when the exact age-, sex-, and treatment period-match was made. In conclusion, we demonstrated the increase of total B cell and plasma B cells during PEG-IFN treatment favored HBsAg seroconversion for IHC, and B cells may play a role in HBV seroconversion.</description><subject>Acquired immune deficiency syndrome</subject><subject>Adult</subject><subject>Age</subject><subject>AIDS</subject><subject>Antigens</subject><subject>B cells</subject><subject>B-Lymphocytes - immunology</subject><subject>Biology and Life Sciences</subject><subject>Carrier State - immunology</subject><subject>Carriers</subject><subject>Case-Control Studies</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Dosage and administration</subject><subject>Female</subject><subject>Flow cytometry</subject><subject>Hepatitis B surface antigen</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Interferon</subject><subject>Interferons - therapeutic use</subject><subject>Liver diseases</subject><subject>Lymphocytes B</subject><subject>Male</subject><subject>Medicine and Health Sciences</subject><subject>Monoclonal antibodies</subject><subject>Peginterferon alfa-2a</subject><subject>Physiological aspects</subject><subject>Plasma</subject><subject>Plasma Cells - immunology</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Research and Analysis Methods</subject><subject>Seroconversion</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk11v0zAUhiMEYmPwDxBEQkJw0eLYsV3fIHUTsEqTJvF1aznOSerKjYvtdOzf49BsatAukGMlsp_3PfE5Pln2skDzgvDiw8b1vlN2vnMdzBEuMaXiUXZaCIJnDCPy-Oj7JHsWwgYhShaMPc1OCMGsJASdZu15rsHakN-Ah9yDVRHqPLr88jws2zyAd9p1e_DBuC43w6N0NHsYAa28N2k3b5y17sZ0bb6D1nQRfJO0XR7X4NXu9nn2pFE2wIvxfZb9-Pzp-8Xl7Or6y-pieTXTTOA4E6guUE0LLSirK0GxYJyJmmK0aBCqtECKa1qouqGaQFUKJegC1azgCpM6zbPs9cF3Z12QY46CxCVjKUGEl4lYHYjaqY3cebNV_lY6ZeTfBedbqXw02oLEnAAUiBHMqxLXiwUQjIDqhuCmoiVNXh_HaH21hVpDF72yE9PpTmfWsnV7yXmBkGDJ4N1o4N2vHkKUWxOGgqgOXH_4b84JFyShb_5BHz7dSLUqHcB0jUtx9WAql6nktGQYD9T8ASqNGrYm1Rsak9YngvcTQWIi_I6t6kOQq29f_5-9_jll3x6xa1A2roOzfUy3LUzB8gBq70Lw0NwnuUBy6Ie7bMihH-TYD0n26rhA96K7BiB_AGJzBL8</recordid><startdate>20201202</startdate><enddate>20201202</enddate><creator>Cao, Zhenhuan</creator><creator>Meng, Sha</creator><creator>Zheng, Yanhong</creator><creator>Wang, Junli</creator><creator>Wang, Rui</creator><creator>Chen, Xinyue</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4204-1049</orcidid></search><sort><creationdate>20201202</creationdate><title>B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy</title><author>Cao, Zhenhuan ; Meng, Sha ; Zheng, Yanhong ; Wang, Junli ; Wang, Rui ; Chen, Xinyue</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-90d10d51c956db95296769d5208f00bc90a7c51adf5c3eb49a9580d617a23da23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Adult</topic><topic>Age</topic><topic>AIDS</topic><topic>Antigens</topic><topic>B cells</topic><topic>B-Lymphocytes - immunology</topic><topic>Biology and Life Sciences</topic><topic>Carrier State - immunology</topic><topic>Carriers</topic><topic>Case-Control Studies</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Dosage and administration</topic><topic>Female</topic><topic>Flow cytometry</topic><topic>Hepatitis B surface antigen</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Interferon</topic><topic>Interferons - therapeutic use</topic><topic>Liver diseases</topic><topic>Lymphocytes B</topic><topic>Male</topic><topic>Medicine and Health Sciences</topic><topic>Monoclonal antibodies</topic><topic>Peginterferon alfa-2a</topic><topic>Physiological aspects</topic><topic>Plasma</topic><topic>Plasma Cells - immunology</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Research and Analysis Methods</topic><topic>Seroconversion</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cao, Zhenhuan</creatorcontrib><creatorcontrib>Meng, Sha</creatorcontrib><creatorcontrib>Zheng, Yanhong</creatorcontrib><creatorcontrib>Wang, Junli</creatorcontrib><creatorcontrib>Wang, Rui</creatorcontrib><creatorcontrib>Chen, Xinyue</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cao, Zhenhuan</au><au>Meng, Sha</au><au>Zheng, Yanhong</au><au>Wang, Junli</au><au>Wang, Rui</au><au>Chen, Xinyue</au><au>Chemin, Isabelle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2020-12-02</date><risdate>2020</risdate><volume>15</volume><issue>12</issue><spage>e0242559</spage><epage>e0242559</epage><pages>e0242559-e0242559</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Our recent study showed high rate of HBsAg seroconversion achieved in inactive HBsAg carriers (IHCs) treated with peginterferon (PEG-IFN). To better understand the immune-mediated component to the HBsAg seroconversion, we investigated the role of B cells in this study. A total of 44 IHCs were given 48 weeks of PEG-IFN. Fifteen cases achieve HBsAg seroconversion (R group), whereas 29 failed (NR group). The proportion of total B cells and plasma B cells were measured before and during treatment. We found that the proportion of total B cells and plasma B cells was no significant between R group and NR group at baseline, but significantly higher in R group than NR group during PEG-IFN treatment, even when the exact age-, sex-, and treatment period-match was made. In conclusion, we demonstrated the increase of total B cell and plasma B cells during PEG-IFN treatment favored HBsAg seroconversion for IHC, and B cells may play a role in HBV seroconversion.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>33264330</pmid><doi>10.1371/journal.pone.0242559</doi><tpages>e0242559</tpages><orcidid>https://orcid.org/0000-0003-4204-1049</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2020-12, Vol.15 (12), p.e0242559-e0242559 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2466255374 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Acquired immune deficiency syndrome Adult Age AIDS Antigens B cells B-Lymphocytes - immunology Biology and Life Sciences Carrier State - immunology Carriers Case-Control Studies Deoxyribonucleic acid DNA Dosage and administration Female Flow cytometry Hepatitis B surface antigen Hepatitis B Surface Antigens - blood Hospitals Humans Interferon Interferons - therapeutic use Liver diseases Lymphocytes B Male Medicine and Health Sciences Monoclonal antibodies Peginterferon alfa-2a Physiological aspects Plasma Plasma Cells - immunology Polyethylene Glycols - therapeutic use Research and Analysis Methods Seroconversion |
| title | B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T21%3A17%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=B%20cells%20were%20related%20to%20HBsAg%20seroconversion%20in%20inactive%20HBsAg%20carriers%20following%20peginterferon%20therapy&rft.jtitle=PloS%20one&rft.au=Cao,%20Zhenhuan&rft.date=2020-12-02&rft.volume=15&rft.issue=12&rft.spage=e0242559&rft.epage=e0242559&rft.pages=e0242559-e0242559&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0242559&rft_dat=%3Cgale_plos_%3EA643546224%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2466255374&rft_id=info:pmid/33264330&rft_galeid=A643546224&rft_doaj_id=oai_doaj_org_article_273ee106327b42d88e320e5cf32fb545&rfr_iscdi=true |